Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 30, Number 2—February 2024
CME ACTIVITY - Synopsis

Multicenter Retrospective Study of Invasive Fusariosis in Intensive Care Units, France

Jordane Demonchy, Lucie Biard, Raphaël Clere-Jehl, Florent Wallet, Djamel Mokart, Anne-Sophie Moreau, Laurent Argaud, Camille Verlhac, Frédéric Pène, Alexandre Lautrette, Naïke Bige, Audrey de Jong, Emmanuel Canet, Jean-Pierre Quenot, Nahéma Issa, Yoann Zerbib, Inès Bouard, Muriel Picard, and Lara ZafraniComments to Author 
Author affiliations: Centre Hospitalier Universitaire de Lille, Lille, France (J. Demonchy, A.-S. Moreau); Institut national de la santé et de la recherche médicale (INSERM), University of Paris Cité, Paris, France (J. Demonchy, L. Zafrani); Hôpital Saint-Louis, Paris (L. Biard, I. Bouard, L. Zafrani); Centre Hospitalier Universitaire de Strasbourg, Strasbourg, France (R. Clere-Jehl); Centre Hospitalier Universitaire de Lyon, Lyon, France (F. Wallet, L. Argaud); Institut Paoli-Calmettes, Marseille, France (D. Mokart); Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France (C. Verlhac, A. Lautrette); Hôpital Cochin, Paris (F. Pène); Hôpital Saint-Antoine, Paris (N. Bige); Montpellier University, INSERM, and St-Eloi Hospital, Montpellier, France (A. de Jong); Centre Hospitalier Universitaire de Nantes, Nantes, France (E. Canet); Centre Hospitalier Universitaire de Dijon Bourgogne, Dijon, France (J.-P. Quenot); Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France (N. Issa); Centre Hospitalier Universitaire de Amiens-Picardie, Amiens, France (Y. Zerbib); Centre Hospitalier Universitaire de Toulouse, Toulouse, France (M. Picard)

Main Article

Table 1

Clinical and biologic characteristics among 55 patients in a multicenter retrospective study of invasive fusariosis in intensive care units, France*

Characteristics Value
Median age, y (IQR)
 61 (52–67)
Sex
M 39 (71)
F
 26 (29)
Immunocompromise type 44 (80)
Hematologic malignancy 16 (36)
Allo-HSCT 16 (36)
Solid organ transplant 11 (20)
Kidney transplant 2 (18)
Liver transplant 4 (36)
Kidney-liver transplant 1 (9)
Lung transplant 3 (27)
Heart transplant 1 (9)
Rheumatoid arthritis with corticosteroids 1 (2)
Diabetes mellitus
 10 (18)
Immunosuppressive agents
Corticosteroids >3 weeks 12 (22)
Other immunosuppressive therapy 22 (40)
Chemotherapy <3 mo
 21 (38)
Biologic data
Neutropenia, neutrophil <0.5 G/L 22 (40)
Lymphopenia, lymphocytes <1 G/L 47 (85)
Hypoalbuminemia, albumin <35 g/L
 48 (87)
Antifungal prophylaxis 13 (24)
Posaconazole 9 (16)
Voriconazole 2 (4)
Fluconazole
 2 (4)
Performance status at admission
>2 30 (55)
<2
 25 (45)
Median prognostic scores at admission (IQR)
SAPS II 54 (40–65)
SOFA at admission 9 (6–13)

*Values are no. (%) except as indicated. Allo-HSCT, allogeneic hematopoietic stem cell transplantation; IQR, interquartile range; SAPS II, simplified acute physiology score II; SOFA, sequential organ failure assessment.

Main Article

Page created: November 30, 2023
Page updated: January 22, 2024
Page reviewed: January 22, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external